NIH SenNet Consortium: Mapping senescent cells in the human body to understand health and disease

SenNet Consortium

Authors

Writing Group: Patty J Lee[1*], Philip Blood[2], Katy Börner[3], Judith Campisi[4], Feng Chen[5], Heike Daldrup-Link[6], Phil De Jager[7], Li Ding[8], Francesca E Duncan[9], Oliver Eickelberg[10], Rong Fan[11], Toren Finkel[12], Vesna Garovic[13], Nils Gehlenborg[14], Carolyn Glass[15], Ziv Bar-Joseph[16], Pragati Katiyar[17], So-Jin Kim[1], Melanie Königshoff[10], George Kuchel[18], Haesung Lee[19], Jun H Lee[20], Jian Ma[21], Qin Ma[22], Simon Melov[4], Kay Metis[23], Ana L Mora[24], Nicolas Musi[25], Nicola Neretti[26], João F. Passos[13], Irfan Rahman[27], Juan Carlos Rivera-Mulia[28], Paul Robson[29.], Mauricio Rojas[24], Ananda L Roy[30], Birgit Schilling[4], Pixu Shi[31], Jonathan Silverstein[23], Vidyani Suryadevera[6], Jichun Xie[31], Jinhua Wang[32], An-Kwok Ian Wong[1], Laura Niedernhofer[28*].

Brown University TDA: Nicola Nerreti[26], Jian Ma[21], Siyuan (Steven) Wang[33]

Buck Institute for Research on Aging TMC/TDA: Hannah Anvari[9], Julia Balough[4], Christopher Benz**[4]**, Joanna Bons[4], Boris Brenerman[4], Judith Campisi[4], Francesca E Duncan[9], William Evans[34], David Furman[4], Akos Gerencser[4], Heather Gregory[35], Malene Hansen[4], Indra Heckenbach[4], Jamie Justice[35], Pankaj Kapahi[4], Simon Melov[4], Natalia Murad[4], Amy O'Broin[4], Mary Ellen Pavone[9], Mark Powell[4], Birgit Schilling[4], Gary Scott[4], Elisheva Shanes[36], Mahalakshmi Shankaran[34], Eric Verdin[4], Daniel Winer[4], Fei Wu[4].

Consortium Organization and Data Coordinating Center (CODCC): Andrew Adams[2], Philip D. Blood[2], Katy Börner[3], Andreas Bueckle[3], Ivan Cao-Berg[2], Hao Chen[16], Michael Davis[23], Shane Filus[2], Nils Gehlenborg[14], Yuhan Hao[37], Austin Hartman[37], Euxhen Hasanaj[16], Jesse Helfer[23], Bruce Herr II[3], Ziv Bar-Joseph[16], Kay Metis[23], Gesmira Molla[37], Gloria Mou[2], Juan Puerto[2], Ellen M. Quardokus[3], Alexander J. Ropelewski[2], Matt Ruffalo[16], Rahul Satija[37], Melissa Schwenk[23], Robin Scibek[2], William Shirey[23], Max Sibilla[23], Jonathan C. Silverstein[23], Joel Welling[2], Zhou Yuan[23].

Columbia TMC: Richard Bonneau[38], Angela Christiano[39], Benjamin Izar[40], Vilas Menon[41], David M Owens[42], Hemali Phatnani[41], Colin Smith[43], Yousin Suh[39], Andrew F Teich[41].

Duke University TMC: Valerie Bekker[1], Cliburn Chan[31], Elias Coutavas[1], Carolyn Glass[15], Matthew G Hartwig[44], Zhicheng Ji[31], So-Jin Kim[1], Haesung Lee[19], Patty J Lee[1], Andrew B Nixon[19], An-Kwok Ian Wong[1].

Massachusetts General Hospital TDA: Zhixun Dou[45], Jayaraj Rajagopal[45], Nikolai Slavov[46].

Mayo Clinic TDA: David Holmes III[13], Diana Jurk[13], James L Kirkland[47], Anthony Lagnado[13], João F. Passos[13], Tamara Tchkonia[13].

National Institute of Health (NIH): Kristin Abraham[48], Amanda Dibattista[49], Yih-Woei Fridell[17], T.Kevin Howcroft[50], Chamelli Jhappan[51], Pragati Katiyar[17], Viviana Perez Montes[17], Mercy Prabhudas[52], Haluk Resat[53], Ananda L. Roy[30], Veronica Taylor[30].

Stanford TDA: Heike Daldrup-Link[6], Manoj Kumar[6], Vidyani Suryadevara[6].

University of Connecticut TMC: Francisco Cigarroa[25], Rachel Cohn[18], Elise Courtois[29], Jeffrey Chuang[29], Monica Davé[29], Sergii Domanskyi[29], Elizabeth Ann Lieser Enninga[13], Giray Naim Eryilmaz[29], Vesna Garovic[13], Jon Gelfond[29], James Kirkland[47], George A. Kuchel[18], Chia-Ling Kuo[18], Julia S. Lehman[13], Cristina Aguayo-Mazzucato[54], Alendander Meves[13], Nicolas Musi[25], João F. Passos[13], Meenakshi Rani[25], Paul Robson[29], Shane Sanders[29], Tamara Tchkonia[13], Asa Thibodeau[29], Stefan Tullius[55], Duygu Ucar[29], Brian White[29], Qian Wu[18], Ming Xu[18], Seiji Yamaguchi[25]

University of Michigan TDA: Naziheh Assarzadegan[56], Chun-Seok Cho[57], Irene Hwang[57], Yongha Hwang[57], Jingyue Xi[58].

University of Minnesota TMC: Oyedele A. Adeyi[59], Constantin F. Aliferis[60], Alessandro Bartolomucci[61], Xiao Dong[62], Mickayla J. DuFresne-To[28], Sayeed Ikramuddin[63], Steve G. Johnson[60], Andrew C. Nelson[59], Nicola Neretti[26], Laura J. Niedernhofer[28], Xavier S. Revelo[61], Juan Carlos Rivera-Mulia[28], John M. Sedivy[26], Elizabeth L. Thompson[28], Paul D. Robbins[28], Jinhua Wang[60].

University of Pittsburgh TMC: Katherine M Aird[64], Jonathan K Alder[10], Delphine Beaulieu[10], Marta Bueno[10], Jazmin Calyeca[24], Julián A Chamucero-Millaris[24], Stephen Y Chan[65], Hao Chen[16], Dongjun Chung[22], Anthony Corbett[66], Oliver Eickelberg[10], Toren Finkel[12], Vera Gorbunova[67], Kymberly M Gowdy[24], Aditi Gurkar[12], Jeffrey C Horowitz[24], Qianjiang Hu[10], Ziv Bar-Joseph[16], Gagandeep Kaur[27], Timur O Khaliullin[24], Melanie Königshoff[10], Robert Lafyatis[68], Serafina Lanna[12], Dongmei Li[69], Anjun Ma[22], Qin Ma[22], Ana L. Mora[24], Alison Morris[10], Thivanka M Muthumalage[27], Victor Peters[24], Gloria S Pryhuber[27], Irfan Rahman[27], Brenda F Reader[70], Mauricio Rojas[24], Lorena Rosas[24], John C Sembrat[10], Sadiya Shaikh[27], Hangchuan Shi[69], , Sean D Stacey[70], Claudette St. Croix[71], Qixin Wang[27].

University of Washington TDA: Liangcai Gu[72], Yiing Lin[73], Peter S. Rabinovitch[74], Mariya T. Sweetwyne[74].

Washington University TMC: Maksym Artomov[75], Samuel J. Ballentine[75], Feng Chen[5], Milan G. Chheda[8], Sherri R. Davies[76], Li Ding[8], John F. DiPersio[8], Ryan C. Fields[76], James A. Fitzpatrick[77], Robert S. Fulton[78], Shin-Ichiro Imai[79], Sanjay Jain[5], Tao Ju[80], Vladimir M. Kushnir[81], Daniel C. Link[8], Michael Ben Major[82], Stephen T Oh[83], Daniel Rapp[76], Michael P Rettig[8], Shelia A. Stewart[82], Deborah J. Veis[84], Kiran R. Vij[8], Michael C. Wendl[8], Matthew A. Wyczalkowski[8].

Yale TMC: Rong Fan[11]

*Co-corresponding Author

[1]Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
[2]Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, USA.
[3]Department of Intelligent Systems Engineering, School of Informatics, Computing, and Engineering, Indiana University, Bloomington, IN, USA.
[4]Buck Institute for Research on Aging, Novato, CA, USA.
[5]Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
[6]Department of Radiology, Stanford University, Stanford, CA, USA.
[7]Department of Neurology, Columbia University, New York, NY, USA.

[8]Department of Medicine and McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.

[9]Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

[10]Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

[11]Department of Biomedical Engineering, Yale University, New Haven, CT, USA.

[12]Aging Institute, University of Pittsburgh School of Medicine/UPMC, Pittsburgh, PA, USA.

[13]Mayo Clinic, Department of Physiology and Biomedical Engineering, Rochester, MN, USA.

[14]Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

[15]Department of Pathology, Duke University Hospital, Durham, North Carolina, USA.

[16]Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, USA.

[17]Division of Aging Biology. National Institute on Aging (NIA), Bethesda, MD, USA.

[18]UConn Health Center, Farmington, CT, USA.

[19]Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

[20]Department of Molecular & Integrative Physiology, University of Michigan, MI, USA.

[21]School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, USA.

[22]Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.

[23]Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.

[24]Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA.

[25]University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

[26]Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.

[27]Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.

[28]Department of Biochemistry, Molecular Biology and Biophysics, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA.

[29]The Jackson Laboratory, Farmington, CT, USA.

[30]Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives Office of the Director National Institutes of Health (NIH), Bethesda, MD, USA.

[31]Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.

[32]Department of Medicine, and Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.

[33]Department of Genetics and the Department of Cell Biology, Yale School of Medicine, Yale University, New Haven CT, USA.

[34] Department of Nutritional Sciences & Toxicology, University of Berkeley, Berkeley, CA, USA.

[35]Department of Internal Medicine, Section on Gerontology & Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.

[36]Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

[37]New York Genome Center, New York NY, USA.

[38]Prescient Design, a Genentech accelerator, New York, NY, USA; Dept. of Biology, New York University, New York, NY, USA.

[39]Department of Genetics and Development, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, NY, USA.

[40]Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.

[41]Department of Neurology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, NY, USA.

[42]Department of Pathology & Cell Biology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, USA.

[43]Academic Department of Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

[44]Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA.

[45]Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA USA.

[46]Department of Bioengineering, Northeastern University, Boston, MA, USA.

[47]Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.

[48]Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

[49]Division of Neuroscience, National Institute on Aging (NIA), NIH, Bethesda, MD, USA.

[50]Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA.

[51]Division of Cancer Biology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA.

[52]Division of Allergy, Immunology & Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.

[53]Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives National Institutes of Health (NIH), Bethesda, MD, USA.

[54]Joslin Diabetes Center, Boston, MA, USA.

[55]Brigham and Women's Hospital, Boston, MA, USA.

[56]Department of Pathology, University of Michigan, MI, USA.

[57]Department of Molecular & Integrative Physiology, University of Michigan, MI, USA.

[58]Department of Biostatistics, University of Michigan, MI, USA.

[59]Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.

[60]Department of Medicine, and Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA. [61]Department of Integrative Biology and Physiology, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA.

[62]Department of Genetics, Cell Biology, and Development, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA.

[63]Department of Surgery, University of Minnesota, Minneapolis, MN, USA.

[64]Department of Pharmacology and Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

[65]Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

[66]Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.

[67]Departments of Biology and Medicine, University of Rochester, Rochester, NY, USA.

[68]Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

[69]Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, USA.

[70]Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

[71]Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

[72]Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.

[73]Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.

[74]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

[75]Department of Pathology and Immunology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[76]Department of Surgery, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[77]Department of Neuroscience, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[78]Department of Genetics and the McDonnell Genome Institute, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[79]Department of Developmental Biology, Washington University in St. Louis, St. Louis, MO, USA.

[80]Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, MO, USA.

[81]Department of Medicine, Division of Gastroenterology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[82]Department of Cell Biology and Physiology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[83]Department of Medicine, Division of Hematology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

[84]Department of Medicine, Division of Bone and Mineral Diseases, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA.

*Corresponding Author: Patty J Lee, MD

- Address: 3110 MSRB 3, 3 Genome Court, Durham, NC 27710
- Phone: (919) 684-0928
- Email: patty.lee@duke.edu

*Corresponding Author: Laura Niedernhofer

- Address: 4-110 NHH, 321 Church St. SE, Minneapolis, MN 55455
- Phone: 612-625-3080
- Email: lniedern@umn.edu

Abstract

Cells respond to a myriad of stressors by senescing, acquiring stable growth arrest, morphologic and metabolic changes, and a senescence-associated-secretory-phenotype (SASP). The heterogeneity of senescent cells (SnCs) and their SASP is vast, yet poorly characterized. SnCs have diverse roles in health and disease and are therapeutically targetable, making characterization of SnCs and harmonization of their nomenclature a priority. The Cellular Senescence Network (SenNet), a NIH Common Fund initiative, will leverage emerging single cell and spatial-omics to identify and map SnCs in numerous organs across the lifespan of humans and mice. A common coordinate framework will integrate the data, using validated, standardized methods, creating public 4-dimensional SnC atlases. Key SenNet deliverables include development of innovative tools/technologies to detect SnCs, biomarker discovery, common annotations to describe SnCs and extensive public data sets. The goal is to comprehensively understand and map SnCs for diagnostic and therapeutic purposes to improve human health.

Keywords
Cellular Senescence Network, Normal Aging, Senescence, Senescence-associated secretory phenotype, SenNet

Introduction

Senescence is a cell state triggered by numerous types of cell - intrinsic and –extrinsic stress, including mitotic, oxidative, genotoxic, mechanical, or nutrient stress, and organelle dysfunction[1]. Senescence is driven by p53/p21^{CIP1} and p16^{INK4a}/Rb tumor suppressor pathways and possibly other signaling events yet to be identified[1-3]. The senescence response is amplified by several mediators, including ATM, IKK/NF-κB, JAK/STAT, GATA-4, and mTOR. Senescent cells (SnCs) acquire diverse characteristics such as increased cell size and protein content, altered organelle function, evidence of chronic nuclear genotoxic stress, a robust secretome, and resistance to apoptosis[1]. One constant characteristic of SnCs is a stable cell cycle arrest, illustrating the main goal of senescence – to prevent a damaged cell from replicating itself, potentially leading to mutations and the risk of cancer.

Multiple lines of evidence suggest that SnCs drive aging itself, and many diverse age-related diseases in preclinical models[1,4-10]. Reports suggest that interventions targeting SnCs can impact more than one disease of old age[11]. However, at least certain types of SnCs also play important roles in normal physiology, e.g., development and wound healing[12,13]. SnCs have a senescence-associated secretory phenotype (SASP) comprised of diverse molecules, including proinflammatory cytokines, chemokines, growth factors, proteases, receptors, extracellular vesicles, and specific extracellular matrix proteins[14-16]. The SASP can drive the loss of tissue homeostasis and secondary senescence (pathological role). The SASP is also thought to be critical for attracting immune cells that mediate tissue regeneration and clearance of SnCs (normal physiology)[17]. Given the heterogeneity and evolving definitions of SnCs and SASP, there is a need to expand efforts to characterize, detect and integrate SnCs, with deeper ontology-based understanding and standardization of nomenclatures, as well as detection methodologies.

In 2011, it was firmly established that genetic clearance of SnCs delays onset of multiple age-related pathologic conditions affecting numerous tissues in transgenic mice[18]. In 2016 it was established that genetic clearance of SnCs in mice delays all-cause mortality, extending median, but not maximum lifespan[19], thus implicating SnCs in contributing to all diseases that kill mice, including cancer, chronic kidney disease, and cardiomyopathy[19]. These genetic studies incentivized the development of senotherapeutics – drugs that selectively target SnCs, either killing them (senolytics) or suppressing markers of senescence including the SASP (senomorphics). The first senolytics were described in 2015[20]. Since then, dozens of senotherapeutics have been described, including natural products[21,22], repurposed drugs[6,23], peptides[24], proteolysis-targeted chimeras[25], and CAR-T cells[26].

Senolytics have proven efficacious in pre-clinical models of frailty, cardiovascular disease, kidney disease, atherosclerosis, diabetes, osteoarthritis, osteoporosis, hepatic and pulmonary fibrosis, steatosis, obesity, depression, mortality due to acute ß-coronavirus infection, and Alzheimer's disease[27,28]. Currently, there are numerous ongoing clinical trials testing senolytics in a variety of age-related diseases including frailty, idiopathic pulmonary fibrosis, Alzheimer's disease, chronic kidney disease, osteoporosis, and COVID-19 in older adults. Preliminary data from these studies indicate that at least the senolytic cocktail, dasatinib plus quercetin, appears to be safe in humans, reducing SnC burden[29,30]. Moreover, in mice, a short course of senolytics, administered intermittently, is sufficient to improve multiple measures of physical fitness even

when administered late in life[31], highlighting the potential impact of such strategies on human health and healthcare costs.

Nevertheless, despite this promise, there is a lack of information about the identity and heterogeneity of SnCs in human tissues and their unique characteristics. Little is known about where and when SnCs arise in humans across lifespan and health status, or the extent of SnC heterogeneity *in vivo,* and release of senescence factors/SASP into blood circulation. Such knowledge could guide therapeutic and organ-specific targeting of SnCs, improving senotherapeutic approaches to treating multi-morbidities associated with aging. Clearly there is a significant need to develop tools to map and identify the types of human SnCs with spatial and temporal resolution over the human lifespan.

Establishment of SenNet: The characterization of human SnCs to date has largely been conducted *in vitro*. SnC characteristics very much depend on cell-type, inducing stimulus, temporal dynamics, and physiological context. Such phenotypic and temporal heterogeneity make it challenging for the scientific community to identify and agree on biomarkers that are common to most SnCs. As a result, no single laboratory, grant, or approach will be adequate to comprehensively define cellular senescence. Yet, a detailed characterization of SnCs and the unique SASP associated with them is urgently needed if we are to harness knowledge about cellular senescence for the benefit of human health. The number of tissues, diseases and conditions affected by the accumulation of SnCs during aging and other physiological processes supports the need for a community-wide scientific effort to tackle this challenge. The Common Fund occupies a unique and exciting space at NIH and is specifically designed to address large challenges and opportunities that are of high priority for the entire NIH (all 27 institutes and centers) and the biomedical community broadly.

In 2021, the NIH Common Fund launched the Senescence Network (SenNet) program with the goal of identifying and functionally characterizing SnCs in healthy human tissues across the human lifespan. The geographic spread of the tissue mapping centers (TMCs) / Technology Development and Application awards (TDAs) are shown in **Fig.1**. This vision of creating a comprehensive atlas of SnCs was catalyzed by several NIH-sponsored workshops engaging experts in senescence working across numerous disciplines who indicated a need to develop novel tools and technologies to identify SnCs *in vivo* and to harmonize data across laboratories to accurately characterize the heterogeneity of SnCs at single cell resolution. Model systems and perturbations to validate the characteristics of SnCs identified in tissues were also identified as needs[32]. While distinct from human models, murine models offer extraordinary value by enabling genetic and pharmacologic manipulation of SnCs and longitudinal assessments to determine how/when cells acquire senescence features, how those features change over time and what the physiologic roles may be in vivo. SenNet will incorporate mechanisms for establishing a murine atlas of SnCs. The SenNet is designed to have a single Consortium Organization and Data Coordinating Center (CODCC) to harmonize and integrate SnC characterization efforts from numerous sites to create an atlas of SnCs across tissues and organisms that captures information about the evolution of senescence in space and time (Four dimensional (4D) atlases). These efforts will be of immeasurable value to the broader biomedical community, while addressing incredible challenges that will require technological advances for the following reasons.

Figure 1. Geographic distribution of 2021 SenNet Awards focused on mapping SnCs in human tissues. TMC = Tissue Mapping Center (RFA-RM-21-008 U54); TDA = Technology Development and Application (RFA-RM-21-009 UG3/UH3), CODCC = Consortium Organization and Data Coordinating Center (RFA-RM-21-010 U24). Bold font identifies institutes of contact PIs.

Characterization of SnCs: The complexity of the senescence response entails kinetic alterations in virtually all aspects of a cell's biology, from epigenetic remodeling of chromatin[33] to changes in the quantity and function of organelles[34]. Current biomarkers used to identify SnCs include increased expression of the cell cycle regulators $p16^{INK4a}$ [35] and $p21^{CIP1}$ [36], increased lysosomal senescence-associated β-galactosidase activity (SA-βgal)[37], decreased Lamin B1[38], secretion of HMGB1[39], and several markers of genotoxic stress. These include SADFs (senescence-associated DNA damage foci characterized by co-localization of γH2AX and 53BP1), TAFs/TIFs (telomere-associated or telomere dysfunction-induced foci characterized by γH2AX foci at telomeres)[40], SAHFs (senescence-associated heterochromatic foci characterized by co-localization of dense DAPI staining and modified histones) and SADS (senescence-associated distensions of satellite DNA characterized by CENP-B foci at centromeres). In addition, activation of LINE-1 retrotransposable elements[41,42], and cytoplasmic chromatin fragments[43], as well as mitochondrial DNA[44], have also been described as stress markers. None of these molecular endpoints are specific to SnCs, which suggest the need to measure multiple endpoints to more precisely identify senescence[1,45]. Most published studies to date rely on bulk tissue analysis or, if at single cell resolution, implement a singular approach (e.g., transcriptomics, CyTOF), neither of which is adequate to identify SnCs lineages with the precision necessary to move the field forward – particularly in the therapeutic realm. Numerous other molecules have been attributed to SnCs or their SASP. However, in the absence of cross-validation with established (yet non-specific) SnC biomarkers at the level of single cell resolution and validation

with appropriate perturbations provoking or targeting SnCs, these molecules are only _potential_ biomarkers of SnCs. Hence, there is a significant need for a creative, comprehensive, and most importantly united approach (in terms of cross-validation to establish rigor and reproducibility) to characterize SnCs at single cell resolution in tissues and _in vivo._

SnC Atlas: Other challenges to creating a 4D SnC atlas include: 1) SnCs are rare _in vivo_; 2) spatial-omics is currently a nascent technology validated only for mapping of well-characterized cell types, implying an additional burden of validation for ill-characterized cell types such as SnCs; 3) for any single SnC biomarker, it is not yet established whether changes in mRNA, protein or the epigenome (or some combination) best reflect a senescent state; 4) implementing a biomarker panel that includes a combination of proteins, nucleic acids, morphology markers, and measure of enzymatic activity endpoints limit the ability to co-localize the biomarkers at the single cell resolution; 5) SnCs in different tissues will likely express common as well as tissue-specific patterns of senescence regulators, effectors, and other features; and 6) a lack of tools to confidently discriminate pathological vs. physiological SnCs. In complex tissues, comprising of numerous cell types, both the physiological and pathological roles of SnCs may be occurring in close proximity (e.g., chronic tissue damage foci with adjacent areas of tissue regeneration). Ideally, to optimize senotherapeutics and to minimize side effects of this new class of drugs, one would like to distinguish between SnCs involved in these two processes and to do so using a biomarker measured in an easily accessed tissue or biofluid. This will require tissue mapping advances as well as biomarker discovery in human biofluids.

SenNet Deliverables: The expected deliverables from SenNet include a SnC atlas at single cell resolution for human and murine tissues, novel tools, technologies, and data sets that can be readily accessed, searched, and visualized to enable the broad community to query these sets to better define SnCs. A clear and comprehensive definition of SnCs in various tissues that will yield information about molecular targets unique or enriched in SnCs that could form the basis of selective senotherapeutics to advance the treatment of age-related multi-morbidities as well as diseases. Biomarkers will ideally be validated within and across tissues, ultimately enabling predictive modeling, optimizing SnC targeting and ensuring the safety and efficacy of senotherapeutics in both health maintenance and disease. Finally, it is expected that the SenNet program will interface with other existing cell mapping programs such as Human Bimolecular Atlas Program (HuBMAP), Human Cell Atlas (HCA), and the Kidney Precision Medicine Project (KPMP). Data integration will allow greater identification of translatable intersections as well as deploy common knowledge, data platforms, pipelines, tools, and technologies in an integrated manner to map SnCs.

To achieve the goals of SenNet, a substantial part of the consortium effort is dedicated to establishing multiple TMCs. Each TMC is charged with creating 4D atlases of at least two human or five murine tissues at the single cell level via emerging spatial mapping techniques including multiplexing of imaging, proteomics, and transcriptomics in tissue sections. Collectively, the TMCs are currently covering 18 primary human tissues (**Fig. 2**). Complementing this atlas construction effort, SenNet also has a significant technology development component. These efforts are designed to explore novel techniques and/or to improve existing methods to detect and characterize the heterogeneity of SnCs at single cell resolution. Examples include deep

Figure 2. Human tissues in which SnCs will be mapped and characterized by SenNet Consortium to produce 4D atlases of senescence across the lifespan of humans.

phenotyping of the 4D nucleome of SnCs, high throughput quantitation of TAFs, and *in vivo* detection of SnCs via PET imaging. Through SenNet, these new technologies will be applied broadly and collaboratively across multiple tissues that will be characterized in SenNet TMCs **(Fig. 2)**.

SnCs are important for normal physiology, including embryonic development, initiation, parturition, tissue regeneration, wound healing, as well as contribute to numerous disease processes. However, whether SnCs are beneficial or deleterious, as thought to occur with aging, is unclear. There is no doubt that a deeper, temporal understanding of SnCs will help research communities to develop therapies that promote the beneficial effects of SnCs while suppressing or removing the deleterious effects. While the current goal of SenNet is mapping of SnCs in "normal/healthy" human and murine tissues to generate reference atlases of SnCs, we anticipate that future efforts will be directed towards leveraging these data sets to study the role of SnCs in various age-related pathologies and diseases.

Anticipated Results

The SenNet Consortium is initially focused on advancing our knowledge of the identity and definition of SnCs in healthy human tissue across the age-span. Like tumorigenesis, senescence

is likely not a single state, entity or phenotype. Rather, the molecular identity of any given SnC is ultimately determined by a combination of its cell lineage, surrounding cells and environment, the endogenous or exogeneous stressors driving senescence, and the purpose of that cell entering senescence (e.g., preventing oncogene-mediated proliferation or promoting wound healing). Collectively, these variables are likely to create a unique molecular fingerprint. SenNet aims to address the challenges in defining the heterogeneity of SnCs and their impact on their tissue microenvironment at a single cell resolution, which will require the implementation of an array of cutting-edge enabling technologies to comprehensively identify, profile, and spatially map SnCs across tissues in humans and mice. These technologies are broadly categorized into two groups – bulk/single cell omics and spatial mapping. An overview of the technologies is shown in **Fig. 3**.


Figure 3. Overview of technologies that will be implemented and developed by SenNet Consortium scientists to detect, characterize, and spatially map the location of SnCs. CyTOF = Cytometry by Time-of-Flight; scCITE-Seq = Cellular Indexing of Transcriptomes and Epitopes by Sequencing; sc/snRNA-seq = single cell or single nuclear RNA sequencing; snATAC-seq = single nuclear Assay for Transposase-Accessible Chromatin using sequencing; MiNA = Multiplexed Imaging of Nucleome Architectures; IMC = Imaging Mass Cytometry; CODEX = CO-Detection by inDEXing immunofluorescence; DBiT-seq = deterministic barcoding in tissue for spatial omics sequencing for co-mapping mRNAs and proteins; RNAScope = RNA in situ hybridization visualization of single molecules; MERFISH = multiplexed error-robust fluorescence in situ hybridization; GeoMx = NanoString GeoMx Digital Spatial Profiling; Visium = Visium 10x Genomics molecular profiling; Seq-Scope = a spatial barcoding technology with spatial resolution comparable to optical microscopy; Pixel-Seq = Polony-indexed library sequencing.

Technologies used by SenNet:

Transcriptomic Approaches: To achieve single cell resolution and overcome the scarcity of SnCs, high-throughput single cell and single-nucleus transcriptomic techniques have become mainstay tools for surveying tens of thousands of cells to identify transcriptional signatures in rare cell populations as low as 0.5%, enabling discovery of potential new SnC biomarkers[46,47].

Perturbations that drive or eliminate SnCs will be critical for validating SnC identity in a context-dependent way, which will also help optimize detection methods. Incorporation of antibody-based targeted proteomics, such as CITE-seq[48], allows for the simultaneous measurement of hundreds of protein markers and whole transcriptome to link cell-type information to transcriptional profiling to uncover cell type-specific senescence biomarkers. Aligning SenNet with HuBMAP's Organ Mapping Antibody Panels (OMPAs)[49], Anatomical Structures, Cell Types, plus Biomarkers (ASCT+B) tables[50], and Affinity Reagent groups will leverage incredible experience in SOPs for validating antibodies and the products of that for discerning cell types.

Proteomic Approaches: SenNet investigators are further developing novel single cell mass spectrometry methods[51], for unbiased discovery of proteomic signatures of SnCs. These methods can be scaled to hundreds of thousands of single cells[49]. These methods can be extended to analyzing protein modifications and covariations, which can reflect regulatory processes in SnCs[52]. SenNet investigators will also examine the epigenetic regulation that may drive transcriptional alterations observed in SnCs. Single cell profiling of chromatin accessibility using ATAC (assay for transposase-accessible chromatin) or chromatin modification using ChIP-seq or CUT&Tag, in combination with single cell/single nucleus RNAseq, will allow for simultaneous profiling of the same cells/nuclei for transcriptome and epigenetic changes to define functional senescence signatures at the single cell level. A hallmark of SnCs is the SASP, which will eventually require a combinatorial approach using proteomics, metabolomics and lipidomics analyses, especially when characterizing SASP-associated extracellular vesicles. The SenNet program will employ emerging technologies to measure large panels of secreted proteins from single cells[53], enabling the characterization of SASP in live SnCs. Caveats to characterizing SnCs include the fact that upregulation of cell cycle regulators in SnCs is modest at best and often below detection by single cell methods. SnCs also tend to be morphologically large and fragile, making them potentially incompatible with single cell dissociation methods. Finally, *in vivo* SASPs may be quite distinct from *in vitro*, which is where mouse, and other animal, models can be informative.

Imaging approaches: High resolution molecular and cellular imaging will be also critical for the study of SnCs in the tissue context and the construction of a common coordinate system and organ-specific two-dimensional (2D) and three dimensional (3D) atlases, which is the main goal of the SenNet TMCs. Static universal tissue agnostic senescence markers may not exist. Instead, there are likely dynamic senescence signatures (gene expression patterns anchored by frequent, but unobligated presence of some of the "known" markers and others yet to be identified), that may differ with cell type, age, and environmental stimuli. As such, it is important to use multiplex imaging to study the coexistence of cellular, molecular (RNA, protein, epigenetic, etc.), or even SASP factors as potential senescence biomarkers. SenNet will use a range of multiplexed imaging tools including Imaging Mass Cytometry, Co-Detection by Indexing (CODEX), Single-Molecule Fluorescence *In Situ* Hybridization (smFISH), Multiplexed Error-Robust Fluorescence *In Situ* Hybridization (MERFISH), Spatial Molecular Imaging, Positron Emission Tomography (PET) Imaging, RNAscope, Multiplex Immunofluorescence, Super Resolution Microscopy, Iterative Indirect Immunofluorescence Imaging (4i), Mitochondrial Network Analysis (MiNA) and Lightsheet Microscopy An example of indexing of co-detection

imaging methods is CODEX[54], which relies on DNA-conjugated antibodies and the cyclic addition and removal of complementary fluorescently labeled DNA probes to simultaneously visualize, at subcellular resolution, up to 60 markers on tissue sections.

In parallel, SenNet investigators are developing novel technologies to image select epigenetic signatures in tissues by visualizing 3D nuclear architecture and open chromatin regions[55]. Although feasible to computationally construct 3D atlases using series of 2D images with multiplexed staining, native 3D imaging, such as light sheet microscopy[56], require much larger sampling volumes are required to build atlases. Another limitation of light sheet microscopy is the small number of detectable markers (3-5) available for each run, which would be insufficient for accurate SnC detection. Current efforts within and outside of SenNet are pushing for greater multiplexity in 3D imaging using barcoded antibodies that will ultimately expand the application of 3D imaging in atlas building for rare, heterogeneous cells such as SnCs. These technologies measure a finite panel of RNA or protein targets, therefore integration with single cell multi-omics data will further advance our capacity to computationally incorporate genome-wide information using spatial molecular or cellular tissue maps.

Spatial mapping approaches: The latest advent in Next-Generation Sequencing (NGS)-based spatial omics technologies is poised to bridge the gap to realize both genome scale and cellular resolution in mapping SnCs in tissue. GeoMx allows for profiling thousands of genes in specific regions of interest and Visium 10X Genomics can map whole transcriptome pixel-by-pixel in a tissue section with a spot size of 55 µm. Higher resolution Visium HD, NanoString CosMx and novel technologies such as Seq-Scope[57] and Pixel-Seq developed within SenNet will further enable the mapping of SnCs with single cell or even subcellular resolution. Investigators in SenNet also developed the first spatial multi-omics technology to co-profile whole transcriptomes and hundreds of proteins via deterministic barcoding in tissue followed by NGS (DBiT-seq) with 10 µm pixel size[58]. This was further expanded to spatial epigenome mapping to measure genome-wide chromatin accessibility (spatial-ATAC-seq) or chromatin modification (spatial-CUT&Tag)[59] to link epigenetic regulation to transcriptional or proteomic markers. Integration with high-resolution imaging makes spatialomics the crucial linchpin in connecting mechanistic underpinnings and molecular signatures with morphological features and spatial distribution, critical to construct a map of SnCs in the native tissue environment.

Validation: SenNet investigators will use a variety of *in vitro* approaches to validate characterization of SnCs, including differentiation of hiPSCs organoids[60] and precision cut tissue slices (PCTS) senolytic agents[61]. Organoids contain structural cells, such as epithelial (stem) cells, fibroblasts, and endothelial cells, which can further be supplemented with immune cell populations. As such, organoids are useful tools to determine the autocrine and paracrine mechanisms of SnCs in a multi-cellular 3D assay system. PCTS, which are 300-500 µm tissue slices, have the advantage of allowing multicellular analyses of cells in their natural 3D environment with high spatiotemporal resolution. Organoids and PCTS will be subjected to the single cell high-content technologies described above as well as to 2D and 3D imaging techniques. Using these approaches, two major outcomes are anticipated: 1) the identification of cell- and driver-specific SnC signatures that will increase the precision and sensitivity of SnC detection *in vivo* by providing a basis for imputing perturbation-specific senescence-associated

gene and protein lists with the atlases generated from whole tissues; and 2) information about the selectivity and potential utility of senolytic agents *ex vivo* as well as across SnC types, perturbations and cell states. In this way, novel senolytic and senomorphic agents can be integrated into a validation pipeline.

Discussion

In recent years, advances in single cell technologies have enabled tissue mapping efforts of human tissues at unprecedented resolution, and the NIH Common Fund has rapidly mobilized such technologies for the advancement of human health. The NIH Common Fund is managed by the Office of Strategic Coordination within the Division of Program Coordination, Planning, and Strategic Coordination Office of the NIH Director. Common Fund programs must address emerging scientific opportunities and pressing challenges in biomedical research that are transformative, catalytic, synergistic, cross-cutting, and unique. Examples of these initiatives include the Human Biomolecular Atlas Program[62], and Somatic Cell Genomic Editing[63], 4DNucelome[64] and GTex[65]. This vision of creating a comprehensive blueprint for senescence was catalyzed by community input that indicated the need for development of novel tools and technologies to identify, trace, and track these heterogeneous populations within tissues. What also emerged from internal and external advisory workshop is the recognition that to achieve these goals new model systems and perturbation agents are necessary to validate *in vitro* and *in vivo* observational studies.

Single cell technologies for imaging and deep-phenotyping SnCs have significant clinical and translational potential with diagnostic, monitoring, and predictive applications. Complementary, multi-modality characterization of SnCs will not only deepen our understanding of senescence biology in health but also reveals the clinical significance of SnCs in cancer, fibrosis, metabolic disorders, and diverse degenerative processes that are fundamental to disease. SnC identification, at single cell resolution, organ and whole-body, would launch impactful conceptual, technical, and clinically applicable advancements that prevent, diagnose and/or treat diverse, disease conditions.

A key impetus for aspiring to create SnC 4D tissue atlases is the advent of relatively new classes of drugs and biologics termed senolytics and senomorphics, as defined earlier in this report. Until we can distinguish between beneficial vs detrimental senescence, and understand what SnC sub-types exists, the senescence field is in danger of developing interventions that can be deleterious or carcinogenic. Cutting-edge, emerging multi-omics and imaging tools employed by SenNet scientists will make critical contributions to achieving the high resolution, multi-dimensional molecular Common Coordinate Framework (CCF) that is used in the Human Reference Atlas (HRA). Specifically, SenNet will add cellular atlases of SnCs from most major human tissue types across the lifespan and health span, serving as a valuable resource and a stepping stone to a new era of cellular senescence and aging research.

Common Coordinate Framework (CCF) and Data visualization: The CCF consists of ontologies and reference object libraries, computer software (e.g., user interfaces), and training materials that support the efficient mapping, registration, and exploration of clinically, semantically, and spatially indexed human tissue data. SenNet will extend the HuBMAP CCF that consists of (1) a CCF Specimen Ontology, which provides CCF-relevant demographic and clinical metadata about the specimen and donor (the "who"); (2) a CCF Biological Structure Ontology, which describes "what" part of the body a tissue sample came from; and (3) a CCF Spatial Ontology, which indicates "where" the tissue is located in a 3D reference system. In addition, the CCF defines a "registration process" that makes it possible to annotate data and map it to the 3D reference system, as well as an "exploration process," which facilitates query, analysis, and visual examination of registered tissue data and prediction of properties, e.g., what cell types are commonly located in a specific anatomical structure or what antibodies should be used to identify a desired set of protein biomarkers (**Fig. 4)**. The CCF also provides three-dimensional representations of anatomy that are linked to anatomical structures, cell types, plus biomarker (ASCT+B) tables that provide detailed cell type level information for each organ of interest.[50] Note that the CCF is semantically explicit (i.e., terminology for anatomical structures, cell types, and biomarkers link to existing ontologies, namely Uberon/FMA, CL, and HGNC) as well as spatially explicit (e.g., 3D reference organs are used for registration and exploration). In February 2022, there were ASCT+B tables for 25 organs and there were 50 associated 3D reference object sets (1-4 per organ, e.g., one uterus but 4 kidneys to capture left/right and male/female versions), which represent the size, shape, position, and spatial orientation of major anatomical structures in an organ-specific manner. The ASCT+B tables and associated spatial reference objects represent the human body in a simplified manner as a partonomy where each cell is part of an anatomical structure that are part of larger anatomical structures and ultimately make up the entire body.


Figure 4. Integration of Common Coordinate Framework (CCF) Exploration UI and Vitessce to enable seamless navigation across scales and queries against SenNet data. The CCF Exploration UI enables registered tissue blocks from the Registration User Interface to be explored spatially (via body browser in the left screenshot, center) and using ontology terms (via hierarchy in the left screenshot, on left) at anatomic scale. A click on a tissue dataset (left screenshot, right) leads to Vitessce (right screenshot) which supports the exploration of cellular and molecular scale distributions. In summary, EUI provides clinical and spatial context and ontology crosslinks, while Vitessce supports details on-demand at the molecular scale.

The SenNet CCF Atlas and SenNet CODCC Data Portal will serve as the "hub" for a hub-and-spoke model of data coordination-integration, which will facilitate future systematic, standardized indexing of clinical, spatial and semantic metadata allowing harmonization amongst

complementary meta data sets, such as HuBMAP. Armed with data sets from "normal" reference maps of senescence, along with requisite tools and technologies, one could envision studying senescence in relevant disease models and physiological systems along with focused studies of senolytics / senomorphics and other pharmacologic and biologic agents. Future extensions of the CCF will require closer integration of Electronic Health Record (EHR) data for characterization and integration into the current medical workflow. Building upon current efforts, future work would require integrating specimen ontology with clinical informatics and EHR-based clinical data for longitudinal data collections to characterize not just the state of patient when the sample was drawn, but the evolution of the person over their entire lifetime. This would naturally capture health characteristics, phenotypes and diseases in evolution, functioning as both markers for comorbidities as well as reference points, or even predictors, for health and disease trajectory. Furthermore, this may serve as an integration point for environmental factors or cumulative drug exposures a person may face over their lifetime within a health system. Such examples may then be used for interpretation of an individual's "health" atlas using artificial intelligence platforms.

Future Perspectives: While the current vision of SenNet is to identify and functionally characterize the heterogeneity of senescent cells across multiple human tissues in a lifespan at single cell resolution, future directions could expand to apply the knowledge to better understand the role of SnCs in various disease states. In addition, how senolytics, senomorphs and other pharmacological agents can be utilized for preventative or therapeutic purposes could also be developed. Importantly, we envision utilizing SenNet's emerging senescence biomarkers studies to monitor health, disease progression and response-to-therapeutics. Novel technologies will be developed and applied to characterize SnCs in human tissues, while new model systems can probe, perturb and validate senescence in various physiological contexts. SenNet will undoubtedly pave the way for exciting, limitless possibilities in the geroscience.

Methods
TMC and TDA
Each individual often multi-site TMC or TDA center will apply their own specific technological measurements (detailed **in Fig. 3**) on the various human or murine organs. Collaborations within SenNet TMCs and TDAs are established throughout this work, including exchange of tissues between the centers. TMCs and TDAs are the foundation of the SenNet mapping initiatives and the data generated will coalesce into the CODCC.

SenNet Biomarker Working Group
Currently, there are three main phenotypes that characterize SnCs, with the caveat that they are context dependent. In general, 1) SnCs enter an essentially permanent arrest of proliferation; 2) become *relatively* resistant to cell death, and 3) develop a SASP. Ideally, an endpoint associated with each of the three main phenotypes should be measured to determine if a cell is senescent. Relying on a single endpoint is fraught with error. For example, high SA-β-Gal activity is detected in cultured confluent fibroblasts[66,67] and certain activated macrophages[68,69], whereas p16 and p21 can be induced in a reversible manner in certain physiological contexts[68-72]. At present, there is no single, stand-alone marker to identify a SnC. Even more unclear are the markers indicate a cell is "destined" to senescence. As more cell types and physiological contexts are studied, a

senescence-*specific* marker may never emerge. Consequently, several groups are compiling lists of cell traits, mRNAs, proteins, lipids and metabolites that may be used to identify, and ultimately define, SnCs. These efforts are generally scientifically sound and welcome as more cell types and tissues are being interrogated for the presence of SnCs. However, the field should be open to the possibility that this effort may ultimately fail due to heterogeneity in senescence responses. To address this, the SenNet consortium has formed a dedicated working groups, whose overall goal is to curate a database of senescence-associated biomarkers. The short-term goal of this working group is to generate a short list of senescence-associated biomarkers currently used by members of the SenNet consortium. The information collected will include cell type information, in what combinations they occur, the associated reagents and their compatibility with experimental methods and tissues. We expect this list will evolve over time, with some markers being removed due to lack of specificity/sensitivity, and others being added as our understanding of the senescent phenotype improves. Ultimately, this effort will generate a compendium of senescence biomarkers at the tissue and cell-type level, which will be integrated with the ASCT+B tables in collaboration with the HuBMAP CCF and ASCT+B working group.

Clinical-Medical Imaging (**Fig. 5**)
The ability to detect SnCs non-invasively and longitudinally in people would substantially improve our ability to monitor the effects of injury, inflammation, development of carcinogenesis, autoimmunity and potential responsiveness to specific drugs or biologics, ultimately identifying those who may benefit from senotherapies. However, to date the development of imaging biomarkers for *in vivo* detection of SnCs has received surprisingly little attention. Initial reports describe fluorescent biomarkers for the detection of SnCs with two-photon microscopy. Vats *et al.* used quantitative liver intravital microscopy to visualize SnCs in young and aged mouse liver using AF488-anti-p21[CIP1] antibody[73]. In addition, radioactive probes have been used for real-time *in vivo* tracking of SnCs with positron emission tomography (PET), integrated PET/computed tomography (PET/CT), microCT for mouse models, and integrated PET/MRI: For example, Koslowsky *et al.* used ^{18}F-labelled antisense oligonucleotide probes to monitor expression of the p21 in human colon carcinoma cells using PET imaging[74]. Krueger *et al.* described the detection of SnCs in colorectal tumors in mice with the radiotracer [^{18}F] FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) and integrated PET/CT and PET/MRI[75]. Qiu *et al.* developed a novel near-infrared fluorescent probe to detect SA-β-Gal activity in KSL0401 cells using fluorescence imaging[76]. Furthermore, recent advances in radioluminescence imaging improved analyses of single cell pharmacokinetics by incorporating two scintillators instead of one, which increases microscope sensitivity and thereby reduces image acquisition times. Kim *et al.* performed radioluminescence imaging using a low-light microscope on MDA-MB-231 cells labeled with radioactive glucose analogue [^{18}F] FDG, as a radiotracer[77].

Another marker, albeit non-specific, for SnCs is reduced cell saturation density at confluence and this could be measured using laser scanning cytometry, which is a microscope-based quantitative-image analyzer offering dual advantages of flow cytometry and image analysis as demonstrated by Zhao *et al.* in A549 cells induced to undergo senescence[78]. Oja. *et al.* performed

Figure 5. Flowchart of Novel Imaging Biomarkers for Senescence Imaging: 1) A baseline imaging test may or may not show senescent cells in specific organ systems, at this stage, prospective research can investigate correlation between quantitative senescence imaging biomarkers and clinical outcomes; 2) the presence or absence of senescent cells may be dependent on genetic predisposition or lifestyle factors, 3) people with specific risk factors, such as advanced age or a disease diagnosis, might demonstrate a normal or abnormal imaging test. At this stage, prospective research can investigate correlations between quantitative senescence imaging biomarkers and clinical outcomes; 4) as a result of senescence imaging tests senotherapies may be used. Prospective research can investigate if senescence imaging biomarkers can be used to stratify patients to personalize senotherapies; 5) ultimately, novel senescence imaging tests might predict clinical outcomes.

an automated image analysis using Cell Omics Morphology Explorer software on images of mesenchymal stromal cells acquired by using high-content screening microscope to give information about nine different parameters indicating cell size and shape[79]. Lee *et al.* utilized time-lapse imaging to illustrate how senescent tumor cells build 3D clusters, using a highly malignant cell line MDA-MB-231[80]. Confocal 3D immunostained images were acquired to look at the size growth of SnCs; the time-lapse images showed their emergence from their initial seeding, to migration and then to 3D clusters. Advances in radio imaging, fluorescence-based imaging approaches and imaging techniques to assess cell morphology and will enable detection and tracking of SnCs *in vivo* longitudinally.

Microphysiologic Platforms

Cellular senescence is often interrogated *in vitro*, which is static relative to *in vivo* conditions. Micro-physiologic platforms have overcome the deficiencies of traditional cell culture techniques and revolutionized the ability to culture tissues *ex vivo* in a manner that recapitulates the dynamic flow of nutrient, gas and waste exchange and tissue interactions that more closely recapitulate the *in vivo* micro-environment. Within SenNet, projects will evaluate SnCs using platforms that enable dynamic flow conditions to better mimic *in vivo* cell biology and thereby generate more accurate markers to identify SnCs *in vivo*. These micro-physiologic platforms will enable the study of cellular senescence in diverse modeling platforms and inform drug-testing in a more complex, physiologic biomimetic system. Moreover, they will allow evaluation of cell interactions, both

senescent and non-senescent, to better understand bystander and/or paracrine effects driven by SASP.

Deep Learning Method to Assess Cellular Senescence

A deep neural network classifier, trained on nuclear morphology, can predict senescence using DAPI- or H&E-stained images[81]. This provides an automated and efficient method to characterize SnCs in tissues with spatial detail. U-NET, a convolutional neural network, relies on image segmentation to identify nuclei, which are then normalized to filter out background, standardize size, and mask internal structures. A collection of nuclei can then be assessed for senescence using several predictor models, trained on multiple forms of senescence, such as replicative, ischemia-reperfusion (IR), and drug-induced senescence. Applied to primary human fibroblast cell cultures, the predictor model showed remarkably high accuracy in detecting SnCs, which can now be applied to histological tissue sections. The top performing model, applicable to images of DAPI-stained nuclei in culture, has an f1 score of 94%, accuracy of 95%, and AUC of 0.99. The generalized model, based on feature reduction, had lower performance which was improved using a deep ensemble. Furthermore, the deep ensemble can filter ambiguous predictions by raising the classification threshold to restrict to higher confidence predictions.

With images from several individuals, the predictor showed an age-dependent increase in SnCs in mice and human tissue samples. We can also apply the predictor to samples with disease to determine how disease affects the predicted rate of senescence, relative to age-matched healthy individuals. The predictor generates granular senescence scores, which can be used to compare groups of individuals with different characteristics. For instance, groups of individuals with different gene expression profiles can be evaluated to uncover correlations with senescence. These novel image analytic methods can be focused on key image regions to estimate senescence by tissue (eventually cell) type and help determine how different regions contribute to overall senescence or disease. In one application, images were classified by tissue type using a deep learning model for image segmentation, indicating regions of adipose, connective, and epithelial tissue. Analyzing predicted senescence suggests that senescence develops differently in each region.

The deep learning predictor can produce SnC scores per nucleus, the location of which can be tracked for spatial mapping. The spatial distribution of predicted SnCs in tissues will enable discovery of how senescence propagates locally. The high precision senescence score also enables more detailed and quantitative analysis, such as an association to other factors of the individual (e.g., biological, physiological, environmental, clinical) or tissue (histological characteristics, gene expression levels, or any other quantitative factor). While this approach has great potential, the development of deep learning methods to accurately identify SnCs in tissues based on morphology is still in its infancy and will require an in-depth characterization of the heterogeneity of SnCs in different tissues, which is one of the goals of SenNet.

Bioinformatics approach to catalog SnC biomarkers

Given that there is no widely agreed-upon SnC biomarker list, we leveraged existing search engines such as Uniprot, a protein database. Senescence markers were identified using the

query, "senescence" AND "reviewed: yes" AND organism: "Homo sapiens (Human) [9606]"). Data collection was focused on key words: "senescence", "human specific", and "peer-reviewed". After collecting information on several senescence markers, further details were assembled, including protein function, subcellular location, and tissue specificity. Each individual marker was tagged with relevant PubMed papers documenting this information. The data were downloaded into excel sheets and further organized. The markers were categorized into secreted and non-secreted proteins using "keyword search" as well as sorting through individual markers. Then, the markers were further categorized into protein function and subcellular localization. Once these proteins are validated and integrated with data from the Biomarker and ASCT+B working groups, standardized, validated categories of SnC biomarkers can start to be formulated.

Data Integration and Harmonization
Given the multi-organ and multi-modal data generation envisioned as part of the SenNet program, a structured, cross-team data management, organization, and analysis plan is essential to the success of SenNet. The SenNet CODCC will manage data curation, integration, analysis, atlas creation, and dissemination through the SenNet Data Portal (**Fig. 6**). These data harmonization and integration efforts will be coordinated with Common Fund Data Ecosystem (CFDE) to align the SenNet data for integration with data sets from other Common Fund programs. Uniformly processed molecular and cellular data will be integrated with the CCF and will be the basis for the construction of an atlas of SnCs. To facilitate the development of uniform data processing and quality control pipelines within CODCC, and re-use by other data consumers, CODCC will mandate data submission using common data formats that are aligned with CCF reference atlas construction. Examples are the use of Azimuth for cell type annotation or OMAP-validated antibody panels. Uniform processing pipelines will implement state-of-the-art algorithms for the analysis of imaging, sequencing, and multi-omics data, which will generate standardized data sets that are spatially registered, segmented and annotated using CCF ASCT+B terminology and


Figure 6. The SenNet Consortium and CODCC workflow. Data generated by the TMCs and TDAs are input into the CODCC along with associated metadata. The data sets are organized and de-identified (curation) then analyzed and integrated. The goal is to create an atlas and public database of curated data that can be searched, analyzed, and visualized as 3D images of organs using unified annotations. Identifying, characterizing, localizing SnCs in human tissues is predicted to promote multiple opportunities for improving human health.

hence linked to existing ontologies. Integrated and harmonized data sets will be made available through the data portal, along with the raw data.

The SenNet Data Portal will also integrate the CCF registration and exploration user interfaces (known as RUI and EUI, respectively) and the Vitessce framework in support of exploratory visualization of existing data across levels—from the whole body to single organs to molecular and cellular level data sets and vice versa (**Fig. 4, 7**). Clinical data will also be standardized and shared in an extension of the CODCC / CCF efforts and will be the basis for standardized implementation and association with EHR clinical data in the future.


Figure 7. Summary of SenNet Consortium Goals. High quality experimental data is needed to create a human reference atlas. The evolving reference atlas supports data standardization and federation, making it possible to integrate data from different specimen, laboratories, and assay types. The atlas characterizes the healthy human—from the whole body down to the single cell level; it can be compared across ages and diseases to understand differences, advance research, and improve human health. Use case scenarios for different stakeholders (researchers, practitioners, students) guide atlas construction and usage but also experimental data acquisition and analysis.

References

1   Gorgoulis, V. *et al.* Cellular Senescence: Defining a Path Forward. *Cell* **179**, 813-827, doi:10.1016/j.cell.2019.10.005 (2019).
2   Kirkland, J. L. & Tchkonia, T. Cellular Senescence: A Translational Perspective. *Ebiomedicine* **21**, 21-28, doi:10.1016/j.ebiom.2017.04.013 (2017).
3   Niedernhofer, L. J. *et al.* Nuclear Genomic Instability and Aging. *Annu Rev Biochem* **87**, 295-322, doi:10.1146/annurev-biochem-062917-012239 (2018).
4   Bussian, T. J. *et al.* Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. *Nature* **562**, 578-+, doi:10.1038/s41586-018-0543-y (2018).
5   Camell, C. D. *et al.* Senolytics reduce coronavirus-related mortality in old mice. *Science* **373**, doi:ARTN eabe483210.1126/science.abe4832 (2021).

6   Chang, J. H. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med* **22**, 78-+, doi:10.1038/nm.4010 (2016).

7   Musi, N. *et al.* Tau protein aggregation is associated with cellular senescence in the brain. *Aging Cell* **17**, doi:ARTN e1284010.1111/acel.12840 (2018).

8   Ogrodnik, M. *et al.* Cellular senescence drives age-dependent hepatic steatosis. *Nature Communications* **8**, doi:ARTN 1569110.1038/ncomms15691 (2017).

9   Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of solid organs. *Nature* **594**, 100-+, doi:10.1038/s41586-021-03547-7 (2021).
10   Zhang, P. S. *et al.* Senolytic therapy alleviates A beta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. *Nat Neurosci* **22**, 719-+, doi:10.1038/s41593-019-0372-9 (2019).
11   Kennedy, B. K. *et al.* Geroscience: Linking Aging to Chronic Disease. *Cell* **159**, 708-712, doi:10.1016/j.cell.2014.10.039 (2014).
12   Demaria, M. *et al.* An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA. *Dev Cell* **31**, 722-733, doi:10.1016/j.devcel.2014.11.012 (2014).
13   Wiley, C. D. *et al.* SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells. *Cell Reports* **28**, 3329-+, doi:10.1016/j.celrep.2019.08.049 (2019).
14   Basisty, N. *et al.* A proteomic atlas of senescence-associated secretomes for aging biomarker development. *Plos Biol* **18**, doi:ARTN e300059910.1371/journal.pbio.3000599 (2020).

15   Coppe, J. P. *et al.* Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. *Plos Biol* **6**, 2853-2868, doi:10.1371/journal.pbio.0060301 (2008).
16   Schafer, M. J. *et al.* The senescence-associated secretome as an indicator of age and medical risk. *Jci Insight* **5**, doi:ARTN e13366810.1172/jci.insight.133668 (2020).

17   Ovadya, Y. *et al.* Impaired immune surveillance accelerates accumulation of senescent cells and aging. *Nature Communications* **9**, doi:ARTN 543510.1038/s41467-018-07825-3 (2018).

18   Baker, D. J. *et al.* Clearance of p16(Ink4a)-positive senescent cells delays ageing-associated disorders. *Nature* **479**, 232-U112, doi:10.1038/nature10600 (2011).
19   Baker, D. J. *et al.* Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature* **530**, 184-+, doi:10.1038/nature16932 (2016).

20   Zhu, Y. *et al.* The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* **14**, 644-658, doi:10.1111/acel.12344 (2015).

21   Wang, Y. Y. *et al.* Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. *Aging-Us* **8**, 2915-2926, doi:10.18632/aging.101100 (2016).

22   Yousefzadeh, M. J. *et al.* Fisetin is a senotherapeutic that extends health and lifespan. *Ebiomedicine* **36**, 18-28, doi:10.1016/j.ebiom.2018.09.015 (2018).

23   Zhu, Y. *et al.* Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Aging Cell* **15**, 428-435, doi:10.1111/acel.12445 (2016).

24   Baar, M. P. *et al.* Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. *Cell* **169**, 132-+, doi:10.1016/j.cell.2017.02.031 (2017).

25   He, Y. H. *et al.* Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. *Nature Communications* **11**, doi:ARTN 199610.1038/s41467-020-15838-0 (2020).

26   Amor, C. *et al.* Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* **583**, 127-+, doi:10.1038/s41586-020-2403-9 (2020).

27   Childs, B. G. *et al.* Senescent cells: an emerging target for diseases of ageing. *Nat Rev Drug Discov* **16**, 718-735, doi:10.1038/nrd.2017.116 (2017).

28   Niedernhofer, L. J. & Robbins, P. D. Senotherapeutics for healthy ageing. *Nat Rev Drug Discov* **17** (2018).

29   Hickson, L. J. *et al.* Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446-456, doi:10.1016/j.ebiom.2019.08.069 (2019).

30   Justice, J. N. *et al.* Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. *EBioMedicine* **40**, 554-563, doi:10.1016/j.ebiom.2018.12.052 (2019).

31   Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat Med* **24**, 1246-+, doi:10.1038/s41591-018-0092-9 (2018).

32   Roy, A. L. *et al.* A Blueprint for Characterizing Senescence. *Cell* **183**, 1143-1146, doi:10.1016/j.cell.2020.10.032 (2020).

33   Parry, A. J. & Narita, M. Old cells, new tricks: chromatin structure in senescence. *Mamm Genome* **27**, 320-331, doi:10.1007/s00335-016-9628-9 (2016).

34   Correia-Melo, C. *et al.* Mitochondria are required for pro-ageing features of the senescent phenotype. *Embo J* **35**, 724-742, doi:DOI 10.15252/embj.201592862 (2016).

35   Liu, Y. *et al.* Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. *Aging Cell* **8**, 439-448, doi:10.1111/j.1474-9726.2009.00489.x (2009).

36   Wang, B. *et al.* An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. *Nat Aging* **1**, 962-973, doi:10.1038/s43587-021-00107-6 (2021).

37   Dimri, G. P. *et al.* A Biomarker That Identifies Senescent Human-Cells in Culture and in Aging Skin in-Vivo. *Proceedings of the National Academy of Sciences of the United States of America* **92**, 9363-9367, doi:DOI 10.1073/pnas.92.20.9363 (1995).

38   Freund, A., Laberge, R. M., Demaria, M. & Campisi, J. Lamin B1 loss is a senescence-associated biomarker. *Mol Biol Cell* **23**, 2066-2075, doi:10.1091/mbc.E11-10-0884 (2012).

39   Davalos, A. R. *et al.* p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. *J Cell Biol* **201**, 613-629, doi:10.1083/jcb.201206006 (2013).

40   Hewitt, G. *et al.* Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. *Nat Commun* **3**, 708, doi:10.1038/ncomms1708 (2012).

41   De Cecco, M. *et al.* Transposable elements become active and mobile in the genomes of aging mammalian somatic tissues. *Aging (Albany NY)* **5**, 867-883, doi:10.18632/aging.100621 (2013).

42   De Cecco, M. *et al.* L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* **566**, 73-78, doi:10.1038/s41586-018-0784-9 (2019).

43   Dou, Z. *et al.* Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* **550**, 402-406, doi:10.1038/nature24050 (2017).

44   Campisi, J. *et al.* From discoveries in ageing research to therapeutics for healthy ageing. *Nature* **571**, 183-192, doi:10.1038/s41586-019-1365-2 (2019).

45   Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. *Nat Rev Cancer* **15**, 397-408, doi:10.1038/nrc3960 (2015).

46   Fa, B. *et al.* GapClust is a light-weight approach distinguishing rare cells from voluminous single cell expression profiles. *Nat Commun* **12**, 4197, doi:10.1038/s41467-021-24489-8 (2021).

47   Jindal, A., Gupta, P., Jayadeva & Sengupta, D. Discovery of rare cells from voluminous single cell expression data. *Nat Commun* **9**, 4719, doi:10.1038/s41467-018-07234-6 (2018).

48   Stoeckius, M. *et al.* Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods* **14**, 865-868, doi:10.1038/nmeth.4380 (2017).

49   Slavov, N. Scaling Up Single-Cell Proteomics. *Mol Cell Proteomics* **21**, 100179, doi:10.1016/j.mcpro.2021.100179 (2022).

50   Borner, K. *et al.* Anatomical structures, cell types and biomarkers of the Human Reference Atlas. *Nat Cell Biol* **23**, 1117-1128, doi:10.1038/s41556-021-00788-6 (2021).

51   Petelski, A. A. *et al.* Multiplexed single-cell proteomics using SCoPE2. *Nat Protoc* **16**, 5398-5425, doi:10.1038/s41596-021-00616-z (2021).

52   Slavov, N. Learning from natural variation across the proteomes of single cells. *Plos Biol* **20**, e3001512, doi:10.1371/journal.pbio.3001512 (2022).

53   Lu, Y. *et al.* Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands. *Proc Natl Acad Sci U S A* **112**, E607-615, doi:10.1073/pnas.1416756112 (2015).

54   Black, S. *et al.* CODEX multiplexed tissue imaging with DNA-conjugated antibodies. *Nat Protoc* **16**, 3802-3835, doi:10.1038/s41596-021-00556-8 (2021).

55   Liu, M. *et al.* Multiplexed imaging of nucleome architectures in single cells of mammalian tissue. *Nat Commun* **11**, 2907, doi:10.1038/s41467-020-16732-5 (2020).

56   Jiang, Z. *et al.* Recent advances in light-induced cell sheet technology. *Acta Biomater* **119**, 30-41, doi:10.1016/j.actbio.2020.10.044 (2021).

57   Cho, C. S. *et al.* Microscopic examination of spatial transcriptome using Seq-Scope. *Cell* **184**, 3559-3572 e3522, doi:10.1016/j.cell.2021.05.010 (2021).

58   Liu, Y. *et al.* High-Spatial-Resolution Multi-Omics Sequencing via Deterministic Barcoding in Tissue. *Cell* **183**, 1665-+, doi:10.1016/j.cell.2020.10.026 (2020).

59   Deng, Y. X. *et al.* Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level. *Science* **375**, 681-+, doi:10.1126/science.abg7216 (2022).

60   Kim, J., Koo, B. K. & Knoblich, J. A. Human organoids: model systems for human biology and medicine. *Nat Rev Mol Cell Bio* **21**, 571-584, doi:10.1038/s41580-020-0259-3 (2020).

61   Alsafadi, H. N. *et al.* Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices Disease Modeling and Drug Discovery. *Am J Resp Cell Mol* **62**, 681-691, doi:10.1165/rcmb.2019-0276TR (2020).

62   Hu, B. C. The human body at cellular resolution: the NIH Human Biomolecular Atlas Program. *Nature* **574**, 187-192, doi:10.1038/s41586-019-1629-x (2019).

63   Saha, K. *et al.* The NIH Somatic Cell Genome Editing program. *Nature* **592**, 195-204, doi:10.1038/s41586-021-03191-1 (2021).

64   Dekker, J. *et al.* The 4D nucleome project. *Nature* **549**, 219-226, doi:10.1038/nature23884 (2017).

65   Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-585, doi:10.1038/ng.2653 (2013).

66   Leontieva, O. V. & Blagosklonny, M. V. Gerosuppression in confluent cells. *Aging-Us* **6**, 1010-1018, doi:DOI 10.18632/aging.100714 (2014).

67   Severino, J., Allen, R. G., Balin, S., Balin, A. & Cristofalo, V. J. Is beta-galactosidase staining a marker of senescence in vitro and in vivo? *Exp Cell Res* **257**, 162-171, doi:DOI 10.1006/excr.2000.4875 (2000).

68   Hall, B. M. *et al.* p16(Ink4a) and senescence-associated beta-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. *Aging-Us* **9**, 1867-1884, doi:10.18632/aging.101268 (2017).

69   Hall, B. M. *et al.* Aging of mice is associated with p16(Ink4a)- and beta-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. *Aging-Us* **8**, 1294-1315, doi:10.18632/aging.100991 (2016).

70   Aix, E., Gutierrez-Gutierrez, O., Sanchez-Ferrer, C., Aguado, T. & Flores, I. Postnatal telomere dysfunction induces cardiomyocyte cell-cycle arrest through p21 activation. *J Cell Biol* **213**, 571-583, doi:10.1083/jcb.201510091 (2016).

71   Puente, B. N. *et al.* The Oxygen-Rich Postnatal Environment Induces Cardiomyocyte Cell-Cycle Arrest through DNA Damage Response (vol 157, pg 741, 2014). *Cell* **157**, 1243-1243, doi:10.1016/j.cell.2014.05.008 (2014).

72   Tane, S. *et al.* CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes. *Biochem Bioph Res Co* **443**, 1105-1109, doi:10.1016/j.bbrc.2013.12.109 (2014).

73   Vats, R. *et al.* Intravital imaging reveals inflammation as a dominant pathophysiology of age-related hepatovascular changes. *Am J Physiol Cell Physiol* **322**, C508-C520, doi:10.1152/ajpcell.00408.2021 (2022).

74   Koslowsky, I., Shahhosseini, S., Mirzayans, R., Murray, D. & Mercer, J. Evaluation of an 18F-labeled oligonucleotide probe targeting p21(WAF1) transcriptional changes in human tumor cells. *Oncol Res* **19**, 265-274, doi:10.3727/096504011x13021877989793 (2011).

75   Krueger, M. A. e. a. in *AACR*   (2019).

76   Qiu, W. J. *et al.* A rapid-response near-infrared fluorescent probe with a large Stokes shift for senescence-associated beta-galactosidase activity detection and imaging of senescent cells. *Dyes and Pigments* **182**, doi:ARTN 10865710.1016/j.dyepig.2020.108657 (2020).

77   Kim, S. R. *et al.* Transplanted senescent renal scattered tubular-like cells induce injury in the mouse kidney. *Am J Physiol-Renal* **318**, F1167-F1176, doi:10.1152/ajprenal.00535.2019 (2020).

78   Zhao, J. *et al.* ATM is a key driver of NF-kappa B-dependent DNA-damage-induced senescence, stem cell dysfunction and aging. *Aging-Us* **12**, 4688-4710, doi:10.18632/aging.102863 (2020).

79   Oja, S., Komulainen, P., Penttila, A., Nystedt, J. & Korhonen, M. Automated image analysis detects aging in clinical-grade mesenchymal stromal cell cultures. *Stem Cell Research & Therapy* **9**, doi:ARTN 610.1186/s13287-017-0740-x (2018).

80   Lee, H. G. *et al.* Senescent tumor cells building three-dimensional tumor clusters. *Sci Rep-Uk* **8**, doi:ARTN 1050310.1038/s41598-018-28963-0 (2018).

81   Heckenbach, I. e. a. Deep Learning Shows Cellular Senescence Is a Barrier to Cancer Development. *Nat Aging* **In press** (2022).

Acknowledgements